Optometrists in Wayland, MA Accepting Medicare
5 Optometrists found. Showing 1 - 5
 Dr. Matthew Shear, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 98 Woodridge Rd, Wayland, MA 01778 Phone: 508-358-5656 |
 David V. Regan, O.d., F.a.a.o. Pc, Inc. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 260 Boston Post Rd, Suite 3, Wayland, MA 01778 Phone: 508-358-4757 Fax: 508-358-2323 |
New England Family Eye Optometrist Medicare: Not Enrolled in Medicare Practice Location: 41 Andrew Ave, Wayland, MA 01778 Phone: 508-577-3367 |
 Dr. Marcia Kay Green, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 75 Boston Post Road, Wayland, MA 01778 Phone: 508-358-5659 Fax: 508-358-5717 |
Dr. Deborah Greenberg Baron, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 153 Woodridge Rd, Wayland, MA 01778 Phone: 508-655-5916 |
News Archive
PhotoMedex third quarter 2013 revenues decrease 19% to $45.9 million
PhotoMedex, Inc. today reported financial results for the three and nine months ended September 30, 2013.
Adoption of new technologies can transform healthcare system
According to Julie Klapstein, CEO of leading health information network Availity, LLC, "Technology adoption by health care providers will be a key determinant in the speed with which our nation's health care system is transformed, and the speed at which patients and providers benefit from better clinical outcomes."
Novartis Pharmaceuticals Canada named one of the top employers in Quebec
For the sixth time, Novartis Pharmaceuticals Canada Inc. has been named one of the top employers in Quebec, according to the newly released 2010 annual report of Hewitt's 50 Best Employers in Canada. This is due in large part to the high level of engagement of its 750 employees across Canada, including 350 at its head office in Dorval.
Update on Nymox Pharmaceutical's Phase 3 program for NX-1207
Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The most recent Safety Monitoring Committee meeting of April 30, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 indicated no significant safety concerns for the trials to date.
› Verified 4 days ago
Physical Therapists
Speech-Language Pathologists
Occupational Therapists
Chiropractors
Optometrists